0000899243-21-008085.txt : 20210224 0000899243-21-008085.hdr.sgml : 20210224 20210224184429 ACCESSION NUMBER: 0000899243-21-008085 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210222 FILED AS OF DATE: 20210224 DATE AS OF CHANGE: 20210224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gollob Jared CENTRAL INDEX KEY: 0001821198 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 21675511 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS, SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 TECHNOLOGY SQUARE STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 300 TECHNOLOGY SQUARE STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-22 0 0001815442 Kymera Therapeutics, Inc. KYMR 0001821198 Gollob Jared C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 0 1 0 0 Chief Medical Officer Common Stock 2021-02-22 4 S 0 9104 52.6285 D 75507 D Common Stock 2021-02-23 4 S 0 19285 49.6528 D 56222 D Common Stock 2021-02-24 4 S 0 8675 50.9131 D 47547 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. /s/ Bruce N. Jacobs, as Attorney-in-Fact 2021-02-24